Product Details
| Alternative Name: | MXR, BCRP, ABCG2, CD338 |
| |
| Clone: | BXP-34 |
| |
| Host: | Mouse |
| |
| Isotype: | IgG1 |
| |
| Immunogen: | Mitoxanthone resistant BCRP (breast cancer resistance protein; MXR) overexpressing cell line MCF7MR. |
| |
| UniProt ID: | Q9UNQ0 |
| |
| Species reactivity: | Human
|
| |
| Specificity: | Recognizes an internal epitope of human BCRP. |
| |
| Crossreactivity: | Does not cross-react with human P-glycoprotein, MRP1, MRP2 or MRP5. |
| |
| Applications: | Flow Cytometry, ICC, IHC (FS)
|
| |
| Recommended Dilutions/Conditions: | Immunocytochemistry: Use 1:20-1:50 dilution on acetone fixed cytospin preparations.
Immunohistochemistry (frozen sections): Use 1:20 dilution of BXP-34 on acetone fixed frozen sections followed by incubation with rabbit anti-mouse IgG and a monoclonal mouse APAAP complex. BXP-34 cannot be used on formaldehyde-fixed paraffin-embedded human tissues and tumors.
Suggested dilutions/conditions may not be available for all applications. Optimal conditions must be determined individually for each application. |
| |
| Application Notes: | Immunocytochemistry: cytospin preparations
Not recommended for Western blot. |
| |
| Formulation: | Liquid. In serum free cell culture supernatant containing 0.7% BSA and 0.1% sodium azide. |
| |
| Shipping: | Blue Ice |
| |
| Short Term Storage: | +4°C |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Product Literature References
Effect of ursodeoxycholic acid treatment on the altered progesterone and bile acid homeostasis in the mother‐placenta‐foetus trio during cholestasis of pregnancy: M.C. Estiu, et al.; Br. J. Clin. Pharmacol.
79, 316 (2015),
Abstract;
Full Text
Endocytosis of ABCG2 drug transporter caused by binding of 5D3 antibody: trafficking mechanisms and intracellular fate: M. Studzian, et al.; Biochim. Biophys. Acta
1853, 1759 (2015),
Application(s): Immunofluorescence,
Abstract;
In vitro toxicological effects of estrogenic mycotoxins on human placental cells: Structure activity relationships: C. Prouillac, et al.; Toxicol. Appl. Pharmacol.
259, 366 (2012),
Abstract;
The role of breast cancer resistance protein in acute lymphoblastic leukemia: S.L. Plasschaert, et al.; Clin. Cancer Res.
9, 5171 (2003),
Abstract;
Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia: J.M. Sargent, et al.; Br. J. Haematol.
115, 257 (2001),
Abstract;
Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues: M. Maliepaard, et al.; Cancer Res.
61, 3458 (2001),
Abstract;
Full Text
Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines: G.L. Scheffer, et al.; Cancer Res.
60, 2589 (2000),
Abstract;
Full Text
General Literature References
A multidrug resistance transporter from human MCF-7 breast cancer cells: L.A. Doyle, et al.; PNAS
95, 15665 (1998),
Abstract;
Full Text
